# Clinical trials recruiting in New Jersey: 1,769 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,769 trials recruiting or not yet recruiting with a site in New Jersey, as read on November 19, 2026.

## The full list

Clinical trials recruiting in New Jersey: 1,769 rows for $88.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 31 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/new-jersey

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,769
- Recruiting or not yet: 1,769
- Read on: November 19, 2026

## Trials

The 25 newest of 1,769, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939529 | People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Not yet recruiting | HIV Viremia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939529) |
| November 16, 2026 | NCT07938398 | Premium Cigar Advertising | Rutgers, The State University of New Jersey | Not applicable | Not yet recruiting | Advertising Perceptions, Tobacco Use Intentions | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938398) |
| November 10, 2026 | NCT07928245 | A Study of Brenipatide in Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 2 | Not yet recruiting | Major Depressive Disorder | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928245) |
| November 10, 2026 | NCT07927998 | A Study of Retifanlimab After Chemoradiation in People With Anal Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Anal Squamous Cell Carcinoma, Anal Cancer, Anal Carcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927998) |
| November 5, 2026 | NCT07918989 | A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After... | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Breast Cancer, Breast Cancer Female | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918989) |
| November 4, 2026 | NCT07916259 | The Study of Brave-LC LDN Treatment Trial | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Not yet recruiting | Post-acute COVID-19 Syndrome | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916259) |
| November 3, 2026 | NCT07913672 | A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD) | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD) | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913672) |
| October 30, 2026 | NCT07908056 | Evaluate Precision of the Test for Lactate in Capillary Whole Blood Specimens Using the i-STAT CG4+ Cartridge With the i-STAT 1 Analyzer | Abbott Point of Care | Observational | Not yet recruiting | Lactate | 425 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908056) |
| October 29, 2026 | NCT07905183 | A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Enliven Therapeutics | Phase 3 | Recruiting | Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic... | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905183) |
| October 29, 2026 | NCT07903974 | Multimodal Intervention for Individuals With Posttraumatic Stress Disorder (PTSD) and Hazardous Alcohol Use | University of Michigan | Not applicable | Not yet recruiting | Post Traumatic Stress Disorder PTSD, Hazardous Alcohol Use | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903974) |
| October 28, 2026 | NCT07901751 | Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) | Ray Therapeutics, Inc. | Phase 2/3 | Recruiting | Retinitis Pigmentosa (RP), Inherited Retinal Diseases | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901751) |
| October 28, 2026 | NCT07899892 | A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Breast Cancer, Invasive Breast Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899892) |
| October 26, 2026 | NCT07895511 | A Study of Skipping Radiation Therapy in People With Breast Cancer | Memorial Sloan Kettering Cancer Center | Not applicable | Recruiting | HER2-positive Breast Cancer, Breast Cancer | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895511) |
| October 26, 2026 | NCT07895498 | A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Pancreatic Cancer, Skin Toxicities | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895498) |
| October 26, 2026 | NCT07894991 | Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury | Kessler Foundation | Phase 2 | Recruiting | Spinal Cord Injury, Spasticity | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894991) |
| October 23, 2026 | NCT07891780 | Pharmacokinetics and Safety of a Single Dose of Epinephrine Nasal Spray in Paediatric Allergy Patients | Hikma Pharmaceuticals USA Inc. | Phase 2 | Not yet recruiting | Epinephrine, Hypersensitivity, Immediate, Anaphylaxis | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891780) |
| October 22, 2026 | NCT07890558 | Addressing Spasticity and Motor Function With Epidural Spinal Cord Stimulation | Kessler Foundation | Not applicable | Recruiting | SCI - Spinal Cord Injury, Spasticity | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890558) |
| October 22, 2026 | NCT07890415 | Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis | Memorial Sloan Kettering Cancer Center | Phase 3 | Recruiting | Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of... | 14,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890415) |
| October 21, 2026 | NCT07886801 | A Study of Ropeg-Interferon in People With Polycythemia Vera | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Polycythemia Vera (PV), JAK2 Mutation | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886801) |
| October 21, 2026 | NCT07886268 | A Study to Evaluate the Efficacy and Safety of TP-06 for PCED | Tarsus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Persistent Corneal Epithelial Defect | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886268) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07879638 | A Study to Determine the Effect of Access to Multiple Tobacco Flavor Options on Smoking Abstinence Among Primary Cigarette Smokers Using an... | RAI Services Company | Not applicable | Recruiting | Smoking, Tobacco | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879638) |
| October 15, 2026 | NCT07876843 | The Effectiveness of a Weight-dependent Algorithm for Dosing Vitamin D. | Atlantic Health System | Not applicable | Not yet recruiting | Hypovitaminosis D | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876843) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Hackensack University Medical Center | Hackensack | 131 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | 130 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | 106 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | 95 |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | 74 |
| Memorial Sloan Kettering Bergen | Montvale | 73 |
| Memorial Sloan Kettering Monmouth | Middletown | 71 |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | 71 |
| Morristown Medical Center | Morristown | 63 |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown | 49 |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale | 49 |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | 47 |
| Kessler Foundation | West Orange | 41 |
| Cooperman Barnabas Medical Center | Livingston | 39 |
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge | 37 |
| Rutgers Cancer Institute | New Brunswick | 35 |
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | 34 |
| Monmouth Medical Center | Long Branch | 32 |
| Newark Beth Israel Medical Center | Newark | 32 |
| Cooper University Hospital | Camden | 25 |
| Sidney Kimmel Cancer Center Washington Township | Sewell | 24 |
| Overlook Hospital | Summit | 24 |
| Cooper Hospital University Medical Center | Camden | 24 |
| Astera Cancer Care | East Brunswick | 24 |
| Saint Peter's University Hospital | New Brunswick | 23 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 13 |
| Phase 1 | 164 |
| Phase 1/2 | 131 |
| Phase 2 | 356 |
| Phase 2/3 | 43 |
| Phase 3 | 447 |
| Phase 4 | 43 |
| Not applicable | 341 |
| Observational | 231 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 103 |
| Breast Neoplasms | 100 |
| Neoplasms | 72 |
| Lung Neoplasms | 49 |
| Prostatic Neoplasms | 47 |
| Neoplasm Metastasis | 46 |
| Colorectal Neoplasms | 42 |
| Multiple Myeloma | 40 |
| Endometrial Neoplasms | 38 |
| Leukemia, Myeloid, Acute | 34 |
| Recurrence | 34 |
| Ovarian Neoplasms | 34 |
| Alzheimer Disease | 29 |
| Heart Failure | 29 |
| Squamous Cell Carcinoma of Head and Neck | 29 |
| Pancreatic Neoplasms | 28 |
| Urinary Bladder Neoplasms | 27 |
| Melanoma | 26 |
| Hematologic Neoplasms | 23 |
| Triple Negative Breast Neoplasms | 22 |
| Carcinoma, Renal Cell | 22 |
| Cardiovascular Diseases | 22 |
| Carcinoma, Transitional Cell | 22 |
| Lymphoma | 21 |
| Small Cell Lung Carcinoma | 19 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 244 |
| Rutgers, The State University of New Jersey | 103 |
| National Cancer Institute (NCI) | 54 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 50 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 49 |
| Kessler Foundation | 37 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 29 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 29 |
| Hackensack Meridian Health | 25 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 25 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 23 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 23 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 19 |
| Children's Oncology Group | 19 |
| Alliance for Clinical Trials in Oncology | 18 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 17 |
| NRG Oncology | 15 |
| SWOG Cancer Research Network | 14 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 14 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 13 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 12 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 12 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 11 |
| Cooper Norcross Health | 11 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 10 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New Jersey

- [Truck rental companies in New Jersey, United States](https://specstream.ai/data/businesses/truck-rental-companies/new-jersey-united-states)
- [Towing companies in New Jersey, United States](https://specstream.ai/data/businesses/towing-companies/new-jersey-united-states)
- [Textile manufacturers in New Jersey, United States](https://specstream.ai/data/businesses/textile-manufacturers/new-jersey-united-states)
- [Telephone service providers in New Jersey, United States](https://specstream.ai/data/businesses/telephone-service-providers/new-jersey-united-states)
- [Tax law firms in New Jersey, United States](https://specstream.ai/data/businesses/tax-law-firms/new-jersey-united-states)
- [Sushi restaurants in New Jersey, United States](https://specstream.ai/data/businesses/sushi-restaurants/new-jersey-united-states)
